InspireMD (NSPR) risk factors
Item 1A of every InspireMD, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
58 risks, 16 new, 7 dropped, 11 reworded since the prior year. The risk section is dominated by the recent US commercial launch of CGuard Prime and upcoming trials for SwitchGuard NPS. Increased disclosures focus on US sales execution, clinical trial compliance, single-source component vulnerabilities, and Israeli operational dependencies.
Filed Mar 18, 2026 - FY2024 10-K risk factors
49 risks. InspireMD reports recurring net losses, including $32.0 million for 2024, and holds an accumulated deficit of $254 million. The company relies heavily on the success, FDA approval, and self-commercialization of the CGuard Prime carotid stent system. Operations in Israel expose the company to regional geopolitical conflicts and currency exchange risks.
Filed Mar 12, 2025